Bead type comparison for liver cancer TACE
Part of Cancer, Digestive system clinical trials.
This trial compares two types of tiny beads used in a liver cancer treatment called TACE to see which works better. If you have liver cancer that needs TACE and your liver is still working fairly well, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have liver cancer (HCC) at a stage where TACE is a treatment option, and you cannot or choose not to have surgery, transplant, or ablation.
- Your liver function is good enough (Child-Pugh A or B) and you are generally active (ECOG score 0-2).
- You have at least one measurable tumor in the liver that hasn't been embolized before, and the largest tumor is 10 cm or smaller.
- You are willing to sign a consent form and participate.
- You do not have severe liver or kidney problems, very low blood counts, serious infections, major blood vessel blockage, or allergies to the materials used.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two treatments for people with large liver tumors. One is a liver artery chemotherapy infusion and the other is a chemo-embolization procedure. The study will see which approach works better.
This trial tests a combination of treatments for liver cancer that cannot be removed with surgery. It uses a procedure to block the tumor's blood supply plus two drugs that help the immune system fight the cancer. This may help shrink tumors and slow the disease.
This trial tests whether a liver-directed treatment called TACE (transarterial chemoembolization) after surgery can help prevent liver cancer from coming back in people with high-risk features.
This trial tests whether combining TACE (a liver-targeted chemo procedure) with two medicines—an immune “checkpoint” drug and a blood-vessel blocking drug—can control unresectable hepatocellular carcinoma. It’s designed for people who can’t have surgery or curative ablation, and who still have reasonably strong liver and overall health.
This trial tests whether a newer targeted chemotherapy bead method (DEB-TACE) works better than standard chemo beads (cTACE) for people with liver cancer who already have a TIPS shunt in place. It aims to find a treatment that controls tumors while being safe for patients with this shunt.
This trial is testing a combination of two immunotherapy drugs (sintilimab and bevacizumab) plus a procedure called TACE (chemoembolization) against a targeted therapy pill (lenvatinib) plus TACE for people with advanced liver cancer. The goal is to see which approach works better to shrink tumors and improve outcomes.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.